Trial Profile
A Randomized, Open-label Study of the Effect of Adjuvant Therapy With Adriamycin Plus Cytoxan Followed by Taxotere or Taxotere Plus Xeloda on Overall Survival in Female Patients With High-risk Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2020
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Aromatase inhibitors; Cyclophosphamide; Docetaxel; Doxorubicin; Tamoxifen; Trastuzumab
- Indications Adenocarcinoma; Early breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 28 Apr 2020 Results (n=1427) assessing the prognostic value of the T effector RNA gene signature (Teff) in four studies (BO20289, NO17629, GO25632 and OAM4861G), presented at the 111th Annual Meeting of the American Association for Cancer Research - I.
- 14 Dec 2019 Results (N= 15,457), a metanalysis of prospective randomized trials assessing efficacy of Capecitabine as a part of neo adjuvant or adjuvant therapy in patients with early breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.